Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria.
Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria.
复制标题
根据 NIAID 真菌病研究组标准分析同情使用伊曲康唑治疗侵袭性曲霉病。
DOI：
--
复制
发表时间：
1997
影响因子：
--
通讯作者：
Jeannette Y. Lee
中科院分区：
文献类型：
--
作者：
D. Stevens;Jeannette Y. Lee
背景
侵袭性曲霉病的成功治疗是困难的，新药的位置正在演变。早期的研究表明，伊曲康唑是一种口服唑，对一些患者有效，但患者较少。
方法
同情性使用数据根据先前在多中心试验中应用的标准作为参考点进行分析。评估了125名患者的病程，并对他们的临床环境和反应进行了分类。
结果
总体而言，34例(27%)完全缓解，45例(36%)好转，20例(16%)无变化，26例(21%)恶化。接受不到2周伊曲康唑治疗的亚组的结果比其余组的患者差，鼻窦、中枢神经系统或广播性疾病的患者也是如此。既往治疗、年龄、基础疾病、曲霉病的其他部位、剂量或曲霉菌种类与预后没有密切关系。在有反应的患者中，通常需要几个月的时间才能记录客观改善。接受骨髓移植的患者的情况比以前的报告要好。
结论
伊曲康唑对许多曲霉菌病患者有效。这一庞大的系列支持了早先的结论，即应答率与两性霉素B的报道相似。
BACKGROUND
Successful therapy of invasive aspergillosis is difficult, and the place of new drugs is evolving. Earlier studies, with fewer patients, suggest itraconazole, an oral azole, is effective for some patients.
METHODS
Compassionate use data were analyzed by criteria applied previously in a multicenter trial as a reference point. The course of 125 patients was evaluated and their clinical settings and responses were categorized.
RESULTS
Overall, 34 (27%) had a complete response, 45 (36%) improved, 20 (16%) were unchanged, and 26 (21%) worsened. The subset receiving less than 2 weeks of itraconazole therapy had a worse outcome than the remainder of the group as did patients with sinus, central nervous system, or widely disseminated disease. Prior therapy, age, underlying disease, other sites of aspergillosis, dose, or Aspergillus species did not correlate closely with outcome. In patients who responded, a period of months was commonly required before objective improvement was documented. Patients who underwent bone marrow transplantation fared better than in previous reports.
CONCLUSIONS
Itraconazole is effective in many patients with aspergillosis. This large series supports earlier conclusions that response rates are similar to those reported for amphotericin B.
环孢素和伊曲康唑在心脏和肺移植受者中的相互作用。
影响因子：
39.2
作者：
Kramer,MR;Marshall,SE;Denning,DW;Keogh,AM;Tucker,RM;Galgiani,JN;Lewiston,NJ;Stevens,DA;Theodore,J
通讯作者：
Theodore,J